Gyre Therapeutics Inc. Common Stock (GYRE)

FairStock Score: 34/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I start with business quality. Gyre sells ETUARY (pirfenidone), an approved anti-fibrotic for idiopathic pulmonary fibrosis, and is developing F351 (hydronidone) in Phase 3 for pneumoconiosis and other fibrotic conditions. That is a real commercial product and a meaningful pipeline, but I see no obvious durable moat; biotech economics depend on trials, regulators, pricing, and competition. The numbers are mixed. In fiscal 2025 (the year ended 2025-12-31), revenue was $116.6M and net income was $9.9M, or diluted EPS of $0.02. In fiscal 2024, revenue was $105.8M and net income was $17.9M, or diluted EPS of $0.05. In fiscal 2023, net loss was $85.5M, or diluted EPS of -$1.41. More recently, fiscal Q1 2026 (quarter ended 2026-03-31) had a net loss of $18.6M, or diluted EPS of -$0.10, and fiscal Q2 2026 (quarter ended 2026-06-30) had revenue of $29.1M and a net loss of $14.3M, or diluted EPS of -$0.12. So FairStock's TURNAROUND label — returned to profit after a loss within the last three years — looks fragile. At the 2026-10-13 close of $6.71, market cap is $748.2M. FairStock calculations show P/E -31.95, P/B 6.58, ROE -17.44%, ROCE -5.42%, FCF yield -1.0%, Piotroski 2/9, Altman Z 7.42, and beta 4.83. Low debt (D/E 0.02) helps, but negative free cash flow of -$7.1M and recent losses mean the price offers little margin of safety unless profitability returns.

In plain English: Gyre Therapeutics develops and sells medicines for organ scarring, including an approved lung drug. The business is not consistently profitable: it earned a small profit in fiscal 2025 but lost money in the first two quarters of fiscal 2026, and it is burning cash. At the October 13, 2026 close of $6.71, the price looks expensive compared with the company's net assets and current losses, so it is hard to call it a bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer